Imiquimod 3.75% for field-directed therapy of actinic keratosis: results of a prospective case-series study in Greece.

Angeliki BefonVassiliki TzanetakouAntonios PanagiotopoulosVasiliki ChasapiChristina AntoniouAlexander J Stratigos

Published in: International journal of dermatology (2019)

Imiquimod 3.75% effectively detected and cleared both the clinical and subclinical actinic keratosis lesions across the entire sun-exposed field in this cohort of Greek patients. Treatment was well tolerated.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
mesenchymal stem cells
patient reported outcomes
combination therapy
patient reported